ABVC Seeks Shareholder Approval for 6.6M Share Land Acquisition and New Equity Plan
ABVC is trading near its 52-week low of $0.88 (9.1% above the low) on elevated volume (2.0× avg).
Summary
ABVC BioPharma's revised proxy seeks approval for a land acquisition that could issue up to 6.6 million shares to a related party, plus a new equity plan and ratification of prior awards, against a backdrop of financial distress.
Key Events · Corporate Governance and Compliance · ABVC
-
Land Acquisition Share Issuance
Proposal 3 authorizes issuance of up to 6,638,591 shares at a price not less than $1.00 per share to acquire land in Taoyuan and Hualien, Taiwan, from Board member Shuling Jiang.
-
Related-Party Transaction
The seller of the properties is Ms. Shuling Jiang, a current Board member, making this a related-party transaction requiring corporate approval processes.
-
New Equity Incentive Plan
Proposal 1 seeks approval of the 2026 Equity Incentive Plan with an initial award pool of 1,169,201 shares plus 15% of outstanding shares, and an annual 5% evergreen provision.
-
Ratification of Prior Awards
Proposal 2 ratifies 600,000 shares granted to two advisors since February 16, 2026, at 50,000 shares per advisor per month for six months.
Analysis · ABVC · Life Sciences
ABVC BioPharma is asking shareholders to approve issuing up to 6,638,591 shares at a minimum of $1.00 per share to acquire land in Taiwan from a related party, Board member Shuling Jiang. The company also seeks approval for a new 2026 Equity Incentive Plan and ratification of 600,000 shares already granted to two advisors. This comes amid a going-concern warning and a wider working capital deficit disclosed in the Q2 10-Q filed the same day, raising concerns about dilution and governance.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABVC was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.5M. The 52-week trading range was $0.88 to $3.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.